EP3755698A4 - Agents de dégradation d'egfr et procédés d'utilisation de ceux-ci - Google Patents
Agents de dégradation d'egfr et procédés d'utilisation de ceux-ci Download PDFInfo
- Publication number
- EP3755698A4 EP3755698A4 EP19757199.5A EP19757199A EP3755698A4 EP 3755698 A4 EP3755698 A4 EP 3755698A4 EP 19757199 A EP19757199 A EP 19757199A EP 3755698 A4 EP3755698 A4 EP 3755698A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- degraders
- egfr
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862632830P | 2018-02-20 | 2018-02-20 | |
US201862744089P | 2018-10-10 | 2018-10-10 | |
PCT/US2019/018753 WO2019164932A1 (fr) | 2018-02-20 | 2019-02-20 | Agents de dégradation d'egfr et procédés d'utilisation de ceux-ci |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3755698A1 EP3755698A1 (fr) | 2020-12-30 |
EP3755698A4 true EP3755698A4 (fr) | 2021-10-27 |
Family
ID=67687371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19757199.5A Withdrawn EP3755698A4 (fr) | 2018-02-20 | 2019-02-20 | Agents de dégradation d'egfr et procédés d'utilisation de ceux-ci |
Country Status (5)
Country | Link |
---|---|
US (1) | US20200377477A1 (fr) |
EP (1) | EP3755698A4 (fr) |
AU (1) | AU2019225743A1 (fr) |
CA (1) | CA3088561A1 (fr) |
WO (1) | WO2019164932A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2019225807A1 (en) * | 2018-02-20 | 2020-07-02 | Dana-Farber Cancer Institute, Inc. | Pharmaceutical combinations of EGFR inhibitors and methods of use thereof |
JP2021514397A (ja) * | 2018-02-20 | 2021-06-10 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Egfr阻害剤の組合せ医薬製剤およびその使用法 |
JP2024529298A (ja) | 2021-07-09 | 2024-08-06 | プレキシウム インコーポレイテッド | Ikzf2を調節するアリール化合物及び医薬組成物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009124399A1 (fr) * | 2008-04-11 | 2009-10-15 | Thallion Pharmaceuticals Inc. | Inhibition de la migration cellulaire par une dibenzodiazépinone farnésylée |
WO2017024317A2 (fr) * | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Procédés pour induire la dégradation de protéine ciblée par des molécules bifonctionnelles |
WO2017185023A1 (fr) * | 2016-04-22 | 2017-10-26 | Dana-Farber Cancer Institute, Inc. | Dégradation de la kinase 9 cycline-dépendante (cdk9) par conjugaison d'inhibiteurs de cdk9 avec un ligand de type ligase e3 et leurs procédés d'utilisation |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006061126A2 (fr) * | 2004-12-09 | 2006-06-15 | F. Hoffmann-La Roche Ag | Derives de dibenzoxazepinone |
WO2007056388A2 (fr) * | 2005-11-07 | 2007-05-18 | The General Hospital Corporation | Compositions et procédés de modulation de l’activité de la poly(adp-ribose) polymérase |
RU2016116516A (ru) * | 2008-12-08 | 2018-12-07 | Мандифарма Интернэшнл Корпорейшн Лимитед | Композиции ингибиторов тирозинкиназных рецепторов белков |
WO2016105518A1 (fr) * | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Procédés pour induire la dégradation ciblée de protéines par des molécules bifonctionnelles |
US10702527B2 (en) * | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
-
2019
- 2019-02-20 AU AU2019225743A patent/AU2019225743A1/en not_active Abandoned
- 2019-02-20 CA CA3088561A patent/CA3088561A1/fr active Pending
- 2019-02-20 WO PCT/US2019/018753 patent/WO2019164932A1/fr unknown
- 2019-02-20 US US16/970,874 patent/US20200377477A1/en not_active Abandoned
- 2019-02-20 EP EP19757199.5A patent/EP3755698A4/fr not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009124399A1 (fr) * | 2008-04-11 | 2009-10-15 | Thallion Pharmaceuticals Inc. | Inhibition de la migration cellulaire par une dibenzodiazépinone farnésylée |
WO2017024317A2 (fr) * | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Procédés pour induire la dégradation de protéine ciblée par des molécules bifonctionnelles |
WO2017185023A1 (fr) * | 2016-04-22 | 2017-10-26 | Dana-Farber Cancer Institute, Inc. | Dégradation de la kinase 9 cycline-dépendante (cdk9) par conjugaison d'inhibiteurs de cdk9 avec un ligand de type ligase e3 et leurs procédés d'utilisation |
Non-Patent Citations (2)
Title |
---|
MASTALERZ ET AL: "Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 17, no. 10, 27 April 2007 (2007-04-27), pages 2828 - 2833, XP022049596, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2007.02.050 * |
See also references of WO2019164932A1 * |
Also Published As
Publication number | Publication date |
---|---|
US20200377477A1 (en) | 2020-12-03 |
EP3755698A1 (fr) | 2020-12-30 |
CA3088561A1 (fr) | 2019-08-29 |
AU2019225743A1 (en) | 2020-07-02 |
WO2019164932A1 (fr) | 2019-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3582852A4 (fr) | Système de luminothérapie amélioré et procédés d'utilisation | |
EP3432933A4 (fr) | Adhésifs biocompatibles et leurs procédés d'utilisation | |
EP3758575A4 (fr) | Endoscope et procédé d'utilisation | |
EP3676267A4 (fr) | Inhibiteurs d'egfr et/ou de her2 et procédés d'utilisation | |
EP3852805A4 (fr) | Anticorps anti-lilrb2 et leurs méthodes d'utilisation | |
EP4010481A4 (fr) | Appareil microfluidique et ses procédés d'utilisation | |
EP3589319A4 (fr) | Composés interagissant avec le glycane et méthodes d'utilisation | |
EP3829413A4 (fr) | Endoscope et méthode d'utilisation | |
EP3813633A4 (fr) | Endoscope et procédé d'utilisation | |
EP3860477A4 (fr) | Endoscope et méthode d'utilisation | |
EP4081346A4 (fr) | Appareil microfluidique et ses procédés d'utilisation | |
EP3728323A4 (fr) | Anticorps anti-fzd et méthodes d'utilisation | |
EP3684819A4 (fr) | Anticorps anti-ykl40 et méthodes d'utilisation | |
EP3749343A4 (fr) | Formulation et procédé d'utilisation | |
EP3886853A4 (fr) | Composés diarylhydantoine et leurs procédés d'utilisation | |
EP3706736A4 (fr) | Agents de dégradation de ash1l et méthodes de traitement au moyen de ceux-ci | |
EP3755697A4 (fr) | Agents de dégradation d'egfr et procédés d'utilisation de ceux-ci | |
EP3635000A4 (fr) | Manabodies et procédés d'utilisation | |
EP3752166A4 (fr) | Agents de liaison trialcyne et procédés d'utilisation | |
EP3710589A4 (fr) | Anticorps anti-c1s et procédés d'utilisation | |
EP3755337A4 (fr) | Combinaisons pharmaceutiques d'inhibiteurs d'egfr et leurs procédés d'utilisation | |
EP3761989A4 (fr) | Imidazodiazépinediones et leurs procédés d'utilisation | |
EP3755689A4 (fr) | Inhibiteurs de l'egfr et leurs procédés d'utilisation | |
EP3749691A4 (fr) | Agents de liaison à angptl8 et leurs méthodes d'utilisation | |
EP3694545A4 (fr) | Anticorps pd-l1 humains et leurs procédés d'utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200611 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20210928 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 45/06 20060101ALI20210922BHEP Ipc: A61K 31/5513 20060101ALI20210922BHEP Ipc: C07D 243/38 20060101ALI20210922BHEP Ipc: C07D 243/08 20060101ALI20210922BHEP Ipc: A61P 35/00 20060101ALI20210922BHEP Ipc: C07D 401/14 20060101AFI20210922BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20220426 |